Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Scikit-learn: Machine Learning in Python

Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Müller, A., Nothman, J., Louppe, G., et al. (2012) · arXiv · doi:10.48550/arxiv.1201.0490 · Cited by 71,016

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A new coronavirus associated with human respiratory disease in China

Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688

An introduction to variable and feature selection

GuyonIsabelle, & ElisseeffAndré (2003) · Journal of Machine Learning Research · doi:10.5555/944919.944968 · Cited by 8,354

An Introduction to Variable and Feature Selection.

Guyon, I., & Elisseeff, A. (2003) · Cited by 6,576

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

Clinical and immunological features of severe and moderate coronavirus disease 2019

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633

SARS and MERS: recent insights into emerging coronaviruses

de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S. N. J., Wurfel, M. M., Evans, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004500 · Cited by 2,588

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 35

Expression of SARS-CoV-2 surface glycoprotein fragment 319–640 in E. coli, and its refolding and purification

Fitzgerald, G. A., Komarov, A. M., Kaznadzey, A., Mazo, I. A., & Kireeva, M. L. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.105861 · Cited by 36

Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review

Shafqat, A., Shafqat, S., Alsalameh, S., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835104 · Cited by 37

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint

Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134

Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection

Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., et al. (2021) · doi:10.1101/2021.05.07.21256823 · Cited by 240

An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens

Gillot, C., Douxfils, J., Cadrobbi, J., Laffineur, K., Dogné, J., Elsen, M., Eucher, C., Melchionda, S., Modaffari, É., Tré‐Hardy, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113752 · Cited by 33

Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients

Cheng, L., Zhang, X., Chen, Y., Wang, D., Zhang, D., Yan, S., Wang, H., Xiao, M., Liang, T., Li, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00718-w · Cited by 31

Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain

Karachaliou, M., Moncunill, G., Espinosa, A., Castaño‐Vinyals, G., Jiménez, A., Vidal, M., Santano, R., Barrios, D., Puyol, L., Carreras, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00807-4 · Cited by 36

How should we use convalescent plasma therapies for the management of COVID-19?

Wood, E. M., Estcourt, L. J., & McQuilten, Z. (2020) · Blood · doi:10.1182/blood.2020008903 · Cited by 30

Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis

Nziza, N., Cizmeci, D., Davies, L. R. L., Irvine, E. B., Jung, W., Fenderson, B. A., de Kock, M., Hanekom, W. A., Franken, K. L. M. C., Day, C. L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856906 · Cited by 32

Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients

Yang, H. S., Racine‐Brzostek, S., Karbaschi, M., Yee, J. K., Dillard, A., Steel, P. A. D., Lee, W. T., McDonough, K. A., Qiu, Y., Ketas, T. J., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113008 · Cited by 32

Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines

Kapłonek, P., Deng, Y., Lee, J. S.-L., Zar, H. J., Zavadska, D., Johnson, M., Lauffenburger, D. A., Goldblatt, D., & Alter, G. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101048 · Cited by 32

Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 27

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccinationPreprint

Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 29

Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis

Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30

Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model

Shrivastava, T., Singh, B., Rizvi, Z. A., Verma, R., Goswami, S., Vishwakarma, P., Jakhar, K., Sonar, S., Mani, S., Bhattacharyya, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641447 · Cited by 26

Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection

Gunn, B. M., & Bai, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1976580 · Cited by 28

Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsPreprint

Sholukh, A. M., Fiore-Gartland, A., Ford, E. S., Hou, Y., Tse, L.-P. V., Lempp, F., Kaiser, H., Germain, R. S., Bossard, E. L., Jia, J.-K., et al. (2020) · medRxiv · doi:10.1101/2020.12.07.20245431 · Cited by 25

Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responsesPreprint

Laing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Coggins, S. A., Samuels, E. C., Phogat, S., Yan, L., Moreno, N., Coles, C., et al. (2021) · medRxiv · doi:10.1101/2021.02.10.21251518 · Cited by 29

Current advances in the detection of COVID-19 and evaluation of the humoral response

Huergo, M. A., & Thanh, N. T. K. (2020) · The Analyst · doi:10.1039/d0an01686a · Cited by 27

Lipid and Nucleocapsid N-Protein Accumulation in COVID-19 Patient Lung and Infected Cells

Grootemaat, A. E., van der Niet, S., Scholl, E. R., Roos, E., Schurink, B., Bugiani, M., Miller, S., Larsen, P. W. B., Pankras, J. E., Reits, E. A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01271-21 · Cited by 24

Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity

Favresse, J., Bayart, J., David, C., Gillot, C., Wieërs, G., Roussel, G., Sondag, G., Elsen, M., Eucher, C., Dogné, J., et al. (2022) · Viruses · doi:10.3390/v14081653 · Cited by 26

Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve

Carbonare, L. D., Valenti, M. T., Bisoffi, Z., Piubelli, C., Pizzato, M., Accordini, S., Mariotto, S., Ferrari, S., Minoia, A., Bertacco, J., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00039-7 · Cited by 25

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

Gregory, D. J., Vannier, A., Duey, A. H., Roady, T. J., Dzeng, R. K., Pavlovic, M., Chapin, M. H., Mukherjee, S., Wilmot, H., Chronos, N., et al. (2022) · Virulence · doi:10.1080/21505594.2022.2073025 · Cited by 23

Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning

Röltgen, K., & Boyd, S. D. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042754 · Cited by 25

Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection

Yuen, R. R., Steiner, D., Pihl, R. M. F., Chavez, E. C., Olson, A., Smith-Mahoney, E. L., Baird, L. A., Korkmaz, F. T., Urick, P., Sagar, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614676 · Cited by 22

Understanding Fc function for rational vaccine design against pathogens

Bowman, K. A., Kapłonek, P., & McNamara, R. P. (2023) · mBio · doi:10.1128/mbio.03036-23 · Cited by 26

Comprehensive Immune Profiling Reveals CD56+ Monocytes and CD31+ Endothelial Cells Are Increased in Severe COVID-19 Disease

Dutt, T. S., LaVergne, S. M., Webb, T. L., Baxter, B. A., Stromberg, S., McFann, K., Berry, K., Tipton, M., Alnachoukati, O., Zier, L., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100830 · Cited by 24

SARS‐CoV‐2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design

Maghsood, F., Vanan, A. G., Yadegari, H., Golsaz‐Shirazi, F., Amiri, M. M., & Shokri, F. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2431 · Cited by 25

Epidemiological and Immunological Features of Obesity and SARS-CoV-2

Nilles, E. J., Siddiqui, S. M., Fischinger, S., Bartsch, Y. C., Aubin, M. D. S., Zhou, G., Gluck, M. J., Berger, S., Rhee, J., Petersen, E., et al. (2021) · Viruses · doi:10.3390/v13112235 · Cited by 23

A Dual‐Encoded Bead‐Based Immunoassay with Tunable Detection Range for COVID‐19 Serum Evaluation

Lin, Z., Zhang, J., Zou, Z., Lu, G., Wu, M., Niu, L., & Zhang, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203706 · Cited by 23

COVID-19: The Effect of Host Genetic Variations on Host–Virus Interactions

Chakravarty, S. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00637 · Cited by 23

Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals

Egia‐Mendikute, L., Bosch, A., Prieto‐Fernández, E., Lee, S. Y., Jiménez-Lasheras, B., Río, A. G.-D., Antoñana-Vildosola, A., Bruzzone, C., Bizkarguenaga, M., Embade, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02011-6 · Cited by 24

SARS-CoV-2 Nucleocapsid protein is decorated with multiple N- and O-glycansPreprint

Supekar, N. T., Shajahan, A., Gleinich, A. S., Rouhani, D. S., Heiß, C., & Azadi, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269043 · Cited by 23

Surveying the Side-Chain Network Approach to Protein Structure and Dynamics: The SARS-CoV-2 Spike Protein as an Illustrative Case

Halder, A., Anto, A., Subramanyan, V., Bhattacharyya, M., Vishveshwara, S., & Vishveshwara, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.596945 · Cited by 21

A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens

Gary, E. N., Warner, B. M., Parzych, E. M., Griffin, B. D., Zhu, X., Tailor, N., Tursi, N. J., Chan, M., Purwar, M., Vendramelli, R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102699 · Cited by 21

Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development

Mallano, A., Ascione, A., & Flego, M. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1929205 · Cited by 22

Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals

Tserel, L., Jõgi, P., Naaber, P., Maslovskaja, J., Häling, A., Salumets, A., Žusinaite, E., Soeorg, H., Lättekivi, F., Ingerainen, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709759 · Cited by 22

Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures

Ravichandran, S., Grubbs, G., Tang, J., Lee, Y., Huang, C., Golding, H., & Khurana, S. (2021) · Science Advances · doi:10.1126/sciadv.abi6533 · Cited by 22

Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection

Fong, S., Yeo, N. K., Chan, Y., Goh, Y. S., Amrun, S. N., Ang, N., Rajapakse, M. P., Lum, J., Foo, S., Lee, C. Y., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01142-z · Cited by 21

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI

Bohländer, F., Riehl, D., Weißmüller, S., Gutscher, M., Schüttrumpf, J., & Faust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.700429 · Cited by 21

Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2Preprint

Wilson, P. C., Stamper, C. T., Dugan, H. L., Li, L., Asby, N. W., Halfmann, P., Guthmiller, J. J., Zheng, N., Huang, M., Stovicek, O., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-80476/v1 · Cited by 20

Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant

Aurelia, L. C., Purcell, R. A., Theisen, R. M., Kelly, A., Esterbauer, R., Ramanathan, P., Lee, W. S., Wines, B. D., Hogarth, P. M., Juno, J. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads1482 · Cited by 20

Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset

Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100727 · Cited by 23

Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes

Lasso, G., Khan, S. M., Allen, S. A., Mariano, M. C., Florez, C., Orner, E. P., Quiroz, J. A., Quevedo, G., Massimi, A. B., Hegde, A., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009778 · Cited by 21

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

Schuster, D. J., Karuna, S., Brackett, C., Wesley, M. S., Li, S. S., Eisel, N., Tenney, D., Hilliard, S., Yates, N. L., Heptinstall, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158402 · Cited by 20

Duplex Electrochemical Microfluidic Sensor for COVID‐19 Antibody Detection: Natural versus Vaccine‐Induced Humoral Response

Mazzaracchio, V., Maciel, M. R., Santos, T. P., Toda‐Peters, K., & Shen, A. Q. (2023) · Small · doi:10.1002/smll.202207731 · Cited by 20

SARS-CoV-2 infection reduces quality of sperm parameters: prospective one year follow-up study in 93 patients

Depuydt, C., Bosmans, E., Jonckheere, J., Donders, F., Ombelet, W., Coppens, A., & Donders, G. G. G. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104640 · Cited by 21

Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy

López-Muñoz, A. D., Santos, J. J. D. S., & Yewdell, J. W. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304087120 · Cited by 22

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

Choteau, M., Scohy, A., Messe, S., Luyckx, M., Dechamps, M., Montiel, V., Yombi, J. C., Gruson, D., Limaye, N., Michiels, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06038-5 · Cited by 19

The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia

Wang, C., Li, Y., Kapłonek, P., Gentili, M., Fischinger, S., Bowman, K. A., Sade-Feldman, M., Kays, K. R., Regan, J., Flynn, J. P., et al. (2022) · mBio · doi:10.1128/mbio.01577-22 · Cited by 20

Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies

Reinig, S., & Shih, S. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100666 · Cited by 22

Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts

Bortz, R. H., Florez, C., Laudermilch, E., Wirchnianski, A. S., Lasso, G., Malonis, R. J., Georgiev, G. I., Vergnolle, O., Herrera, N. G., Morano, N. C., et al. (2021) · mSphere · doi:10.1128/msphere.00224-21 · Cited by 20

How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility

Massalska, M., & Gober, H.-J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646894 · Cited by 19

Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis

Cox, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.708665 · Cited by 18

Analysis of long‐term antibody response in COVID‐19 patients by symptoms grade, gender, age, BMI, and medication

Özgöçer, T., Daglı, S. N., Ceylan, M. R., Dişli, F., Uçar, C., & Yıldız, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27452 · Cited by 16

Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses

Portilho, A. I., Lima, G. G., & Gaspari, E. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061503 · Cited by 19

Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for Accurate and Prompt Coronavirus Disease 2019 (COVID-19) Diagnosis Using the Rational Selection of Serological Biomarkers

Lagousi, T., Routsias, J. G., & Spoulou, V. I. (2021) · Diagnostics · doi:10.3390/diagnostics11111970 · Cited by 20

Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19

Peddireddy, S. P., Rahman, S. A., Cillo, A. R., Vijay, G. K. M., Somasundaram, A., Workman, C. J., Bain, W., McVerry, B. J., Methé, B. A., Lee, J. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111020 · Cited by 19

Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain

Pérez‐Olmeda, M., Saugar, J. M., Fernández-García, A., Pérez‐Gómez, B., Pollán, M., Avellón, A., Pastor‐Barriuso, R., de Larrea, N. F., Martín, M., Cruz, I., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105130 · Cited by 18

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern

McNamara, R. P., Maron, J. S., Boucau, J., Roy, V., Webb, N. E., Bertera, H. L., Barczak, A. K., Staff, T., Franko, N., Logue, J. K., et al. (2023) · mBio · doi:10.1128/mbio.00902-23 · Cited by 17

Portable Surface Plasmon Resonance Detector for COVID-19 Infection

Trzaskowski, M., Mazurkiewicz-Pisarek, A., Trzciński, J., Drozd, M., Podgórski, R., ZABOST, A. T., & AUGUSTYNOWICZ-KOPEĆ, E. M. (2023) · Sensors · doi:10.3390/s23083946 · Cited by 17

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination

Motsoeneng, B. M., Manamela, N. P., Kaldine, H., Kgagudi, P., Hermanus, T., Ayres, F., Makhado, Z., Moyo-Gwete, T., van der Mescht, M. A., Abdullah, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231276 · Cited by 14

An original multiplex method to assess five different SARS-CoV-2 antibodies

Favresse, J., Brauner, J., Bodart, N., Vigneron, A., Roisin, S., Melchionda, S., Douxfils, J., & Ocmant, A. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1652 · Cited by 17

Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France

Carrat, F., Lapidus, N., Ninove, L., Blanché, H., Rahib, D., Villarroel, P. M. S., Touvier, M., Severi, G., Zins, M., Deleuze, J., et al. (2021) · Infection · doi:10.1007/s15010-021-01731-5 · Cited by 15

Early antibody responses associated with survival in COVID19 patients

Zhou, Z., Dharmarajan, S. H., Lehtimaki, M., Kirshner, S., & Kozlowski, S. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009766 · Cited by 17

Deciphering Fc-effector functions against SARS-CoV-2

Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19

Reduced COVID-19 mortality linked with early antibodies against SARS-CoV-2, irrespective of age

Vito, D. D., Ciaula, A. D., Palmieri, V. O., Trerotoli, P., Larocca, A. M. V., Montagna, M. T., & Portincasa, P. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.02.010 · Cited by 15

Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood

Campbell, C., Padmanabhan, N., Romero, D., Joe, J., Gebremeskel, M., Manjula, N., Wohlstadter, N., Wohlstadter, R., Goodwin, P., Quintero, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10484-6 · Cited by 14

mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes

Zimmerman, O., Doss, A. M. A., Kapłonek, P., Liang, C.-Y., VanBlargan, L. A., Chen, R. E., Monroy, J. M., Wedner, H. J., Kulczycki, A., Mantia, T. L., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100653 · Cited by 15

Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions

Vandervaart, J. P., Inniss, N. L., Ling-Hu, T., Minasov, G., Wiersum, G., Rosas‐Lemus, M., Shuvalova, L., Achenbach, C. J., Hultquist, J. F., Satchell, K. J. F., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00324-23 · Cited by 15

Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronavirusesPreprint

Klompus, S., Leviatan, S., Vogl, T. J., Kalka, I. N., Godneva, A., Shinar, E., Weinberger, A., & Segal, E. (2020) · medRxiv · doi:10.1101/2020.09.01.20182220 · Cited by 15

Multisystem Inflammatory Syndrome in Children and SARS-CoV-2 Serology

Zeichner, S. L., & Cruz, A. T. (2020) · PEDIATRICS · doi:10.1542/peds.2020-032888 · Cited by 14

Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19

Yamaguchi, T., Shinagawa, T., Kobata, H., & Nakagawa, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.015 · Cited by 14

Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19

Yegiazaryan, A., Abnousian, A., Alexander, L. J., Badaoui, A., Flaig, B., Sheren, N., Aghazarian, A., Alsaigh, D., Amin, A., Mundra, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169297 · Cited by 14

SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner

Jung, W., Abdelnour, A., Kapłonek, P., Herrero, R., Lee, J. S.-L., Barbati, D. R., Chicz, T. M., Levine, K. S., Fantin, R., Loría, V., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114684 · Cited by 13

Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective

Kumar, A., Prasoon, P., Shekhawat, P. S., Pareek, V., Faiq, M. A., Kumari, C., Narayan, R. K., Kulandhasamy, M., & Kant, K. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1840566 · Cited by 12

Advances in understanding the formation and fate of B-cell memory in response to immunization or infection

Kealy, L. C., & Good‐Jacobson, K. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab018 · Cited by 14

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Bartsch, Y. C., Chen, J. W., Kang, J., Burns, M. D., Denis, K. S., Sheehan, M. L., Davis, J. P., Edlow, A. G., Balazs, A. B., Yonker, L. M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00575-w · Cited by 14

Comparative Transcriptomic and Molecular Pathway Analyses of HL-CZ Human Pro-Monocytic Cells Expressing SARS-CoV-2 Spike S1, S2, NP, NSP15 and NSP16 Genes

Sharma, A., Ong, J., Loke, M. F., Chua, E. G., Lee, J., Choi, H., Tan, Y., Lal, S. K., & Chow, V. T. K. (2021) · Microorganisms · doi:10.3390/microorganisms9061193 · Cited by 13

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profilesPreprint

Kapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.31.458247 · Cited by 13

Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune

Timofeeva, A. M., Sedykh, S. E., Ermakov, E. A., Matveev, A. L., Odegova, E. I., Sedykh, T. A., Щербаков, Д. Н., Merkuleva, I. A., Volosnikova, E. A., Nesmeyanova, V. S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213681 · Cited by 12

Oral Supplementation with AHCC®, a Standardized Extract of Cultured Lentinula edodes Mycelia, Enhances Host Resistance against SARS-CoV-2 Infection

Singh, A., Adam, A., Rodriguez, L., Peng, B., Wang, B., Xie, X., Shi, P., Homma, K., & Wang, T. (2023) · Pathogens · doi:10.3390/pathogens12040554 · Cited by 12

The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients’ survival and long COVID

Noviello, M., LORENZO, R. D., Chimienti, R., Maugeri, N., de Lalla, C., Siracusano, G., Lorè, N. I., Rancoita, P. M. V., Cugnata, F., Tassi, E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381091 · Cited by 13

Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

Deakin, C. T., Cornish, G. H., Ng, K. W., Faulkner, N., Bolland, W., Hope, J., Rosa, A., Harvey, R., Hussain, S., Earl, C. P., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.001 · Cited by 12

High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders

Mele, D., Calastri, A., Maiorano, E., Cerino, A., Sachs, M., Oliviero, B., Mantovani, S., Baldanti, F., Bruno, R., Benazzo, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748881 · Cited by 13

Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence

Fuentes‐Villalobos, F., Garrido, J. L. V., Medina, M. A., Zambrano, N., Ross, N., Bravo, F., Gaete-Argel, A., Oyarzún-Arrau, A., Amanat, F., Soto‐Rifo, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.796481 · Cited by 12

SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals

Qaqish, A., Abbas, M. M., Al‐Tamimi, M., Abbas, M. A., Al-Omari, M., & Alqassieh, R. (2022) · Vaccines · doi:10.3390/vaccines10050643 · Cited by 12

Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding—Who Is Binding Who and Why?

Iles, J. K., Zmuidinaite, R., Sadée, C., Gardiner, A. E., Lacey, J., Harding, S. J., Wallis, G. L. F., Patel, R., Roblett, D., Heeney, J. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116050 · Cited by 12

Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons

Prabhu, M., Yang, Y. J., Johnston, C. D., Murphy, E. A., Ketas, T. J., Diaz-Tapia, R., Jurkiewicz, M., Racine‐Brzostek, S., Mohammed, I. A., Sukhu, A. C., et al. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100796 · Cited by 15

Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Geers, D., Sablerolles, R. S. G., van Baarle, D., Kootstra, N. A., Rietdijk, W. J. R., Schmitz, K. S., Gommers, L., Bogers, S., Nieuwkoop, N. J., van Dijk, L. L. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105753 · Cited by 12

T cell control of SARS-CoV-2: When, which, and where?

Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12

SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise

Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12

Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19Preprint

Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443609 · Cited by 12

A look-back at convalescent plasma to treat COVID-19

Garraud, O., Lacombe, K., & Tiberghien, P. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103063 · Cited by 11

Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19

Martynova, E. V., Hamza, S., Markelova, M., Garanina, E. E., Davidyuk, Y. N., Shakirova, V. G., Kaushal, N., Baranwal, M., Stott-Marshall, R. J., Foster, T. L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830715 · Cited by 11

Comparison of the humoral and cellular immunity in COVID-19 convalescents

Топтыгина, А. П., Semikina, E. L., Шакирович, З. Р., & Afridonova, Z. E. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-cot-1809 · Cited by 12

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities

Wang, L., Li, C., Li, W., Zhao, L., Zhao, T., Chen, L., Li, M., Fan, J., Li, J., Wu, C., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2225640 · Cited by 11

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients

Chen, Y., Tong, X., Li, Y., Gu, B., Yan, J., Liu, Y., Shen, H., Huang, R., & Wu, C. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008796 · Cited by 104

Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 32

Early cross-coronavirus reactive signatures of humoral immunity against COVID-19

Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj2901 · Cited by 77

Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals

Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 120